- €10.92bn
- €10.69bn
- €4.07bn
Brief: bioMerieux Receives FDA Clearance For Latest Versions Of Biofire® Filmarray
Europe Research Roundup: Asos, Erste Group, SCHOTT pharma
Europe Research Roundup: Acceler8 Ventures, Hermes, Soitec
BioMerieux shares rise after Q3 sales beat
Biomérieux third-quarter organic sales growth beats expectations (updated)
Refile: CORRECTED-Biomérieux third-quarter sales grew more than expected
Corrected: Biomérieux third-quarter sales grew more than expected
Brief: Biomerieux Q3 Revenue At €1.04 Billion
Europe Research Roundup: Allianz, Mercedes-Benz, Tesco
European life sciences stocks rise on strong sector momentum
Brief: BioMerieux Receives IVDR Class D CE Marking For 2 Syndromic Tests Including MERS-CoV
UBS cuts Diasorin to 'sell' on expectations not reflecting competition fears
Brief: Biomerieux H1 Organic Sales Growth EUR 1.97 Bln, Adjusts Mid-Term Guidance
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Brief: Biomerieux Submits 510(K) To U.S. FDA For Latest Versions Of Biofire Filmarray
Kepler sees European Medtech recovery, starts BioMerieux at 'Buy' as top pick
Europe Research Roundup: Atlas Copco, Lloyds, Poste Italiane
Morgan Stanley sees selective medtech opportunities on growth recovery
Europe Research Roundup: BAT, GEA Group, Qiagen